Biodexa Pharma - Bathi resik saben saham (EPS TTM) BDRX

The biopharmaceutical sector of Biodexa Pharmaceuticals (BDRX) is subject to geopolitical risks and logistics disruptions. Proprietary targeted drug delivery methods to tumors guarantee business stability. Changes in the rolling annual EPS demonstrate profitability, where the -53.68 metric reflects current dynamics. The company is currently actively researching orphan drugs for the therapy of aggressive brain neoplasms amidst a shortage of funds.

BDRX Bathi resik saben siji saham sajrone rolas wulan pungkasan Biodexa Pharma (28.04.2023 - 15.11.2026)

Rincian analitis lan laporan data perusahaan biodexapharma.com (BDRX)

- rega saham lan target rega konsensus:

Rega saham biodexapharma.com|BDRX - Bagan rega target

- rincian nilai pasar emiten:

Kapitalisasi pasar Biodexa Pharmaceuticals|BDRX - Rega Tumbas Perusahaan

- rincian valuasi buku bisnis:

Aset Bersih saben Siji Saham Biodexa Pharmaceuticals|BDRX - Ekuitas Perusahaan|Rasio Kapitalisasi Pasar marang Nilai Buku biodexapharma.com|BDRX - Total Aset Bisnis

- indikator beban kredit lan likuiditas emiten:

Total Utang marang Modal Biodexa Pharmaceuticals|BDRX - Kewajiban jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Biodexa|BDRX - Utang agregat perusahaan|Utang-utang marang kapitalisasi buku Biodexa|BDRX - Utang jangka dawa perusahaan|Kewajiban jangka cendhak perusahaan Biodexa Pharmaceuticals|Likuiditas cepet biodexapharma.com

- data bathi lan kelipatan valuasi:

BDRX - Bathi sawise pajeg|Proyeksi bathi mangsa ngarep Biodexa Pharmaceuticals|BDRX - Nilai perusahaan marang bathi resik|Pangali Forward P/E Biodexa Pharmaceuticals|BDRX - Pangali PEG|Nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan BDRX|BDRX - Pendapatan sadurunge ngurangi bunga, pajak, lan amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Biodexa Pharmaceuticals|BDRX - Bathi resik saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan biodexapharma.com|BDRX - Wutah bathi ing taun lumaku|Prakiraan wutah bathi kanggo taun ngarep Biodexa Pharmaceuticals

- data pendapatan lan penerimaan dodolan:

BDRX - Dodolan perusahaan|Prakiraan volume dodolan Biodexa Pharma|BDRX - Rega marang dodolan|Multiplikator forward rega marang pendapatan Biodexa|BDRX - Wutah dodolan YoY (TTM)

Pambiji fundamental:Biodexa Pharmaceuticals PLC (BDRX)

Produk sing diprodhuksi Biodexa Pharmaceuticals

Net income per share over twelve months measures the portion of equity attributable to a single security after all expenses are deducted. This metric allows an investor to assess the actual efficiency of cash flow generation. By analyzing the annual net income per share chart, one can determine the stability of the business. For Biodexa Pharmaceuticals (BDRX), this indicator reflects the profitability of complex oncology drug distribution systems. Optimizing logistics to clinics directly impacts the final financial result.

Pesaing Biodexa Pharmaceuticals (BDRX)